目的 探討當(dāng)飛利肝寧膠囊聯(lián)合扶正化瘀膠囊治療慢性乙型肝炎肝纖維化的臨床療效。方法 選擇2013年6月-2015年6月南京鼓樓醫(yī)院集團(tuán)宿遷市人民醫(yī)院感染科收治的慢性乙型肝炎肝纖維化患者98例，隨機(jī)分為對照組和治療組，每組各49例。對照組口服扶正化瘀膠囊，5粒/次，3次/d。治療組患者在對照組治療基礎(chǔ)上口服當(dāng)飛利肝寧膠囊，4粒/次，3次/d。兩組患者均連續(xù)治療6個(gè)月。觀察兩組治療前后透明質(zhì)酸（HA）、層黏連蛋白（LN）、Ⅲ型前膠原（PCⅢ）、Ⅳ型膠原（ⅣC）、門靜脈直徑、脾臟厚度、脾靜脈直徑、肝纖維化分期評分、丙氨酸氨基轉(zhuǎn)移酶（ALT）、HBV-DNA的變化情況。結(jié)果 治療后，兩組患者HA、LN、PCⅢ、ⅣC均顯著降低，同組治療前后差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；治療后，治療組HA、LN、PCⅢ、ⅣC低于對照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。兩組門靜脈直徑、脾臟厚度、脾靜脈直徑明顯減小，同組治療前后差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；治療后，治療組門靜脈直徑、脾臟厚度小于對照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組肝纖維化分期、HBV-DNA水平、ALT均顯著降低，同組治療前后差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；治療后，治療組肝纖維化分期、HBV-DNA水平、ALT均低于對照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。對照組和治療組的ALT復(fù)常率分別為93.88%、100.00%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 當(dāng)飛利肝寧膠囊聯(lián)合扶正化瘀膠囊治療慢性乙型肝炎肝纖維化有協(xié)同作用，可顯著改善肝功能，降低肝纖維化指標(biāo)，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical effect of Dangfei Liganning capsules combined with Fuzheng Huayu Capsules in treatment of chronic hepatitis B with liver fibrosis. Methods Patients (98 cases) with chronic hepatitis B with liver fibrosis in Department of Infectious Disease of Suqian People's Hospital co., LTD of Nanjing Gulou Hospital Group from June 2013 to June 2015 were randomly divided into control and treatment groups, and each group had 49 cases. The patients in the control group were po administered with Fuzheng Huayu Capsules, 5 grains/time, three times daily. The patients in the treatment group were po administered with Dangfei Liganning Capsules on the basis of the treatment group, 4 grains/time, three times daily. The patients in two groups were treated for 6 months. After treatment, the changes of HA, LN, PCⅢ, ⅣC, portal vein diameter, spleen thickness, spleen vein diameter, scores of liver fibrosis stage, ALT, and HBV-DNA in two groups before and after treatment were compared. Results After treatment, HA, LN, PCⅢ, and ⅣC in the two groups were significantly reduced, and the difference was statistically significant in the same group (P<0.05). After treatment, HA, LN, PCⅢ, and ⅣC in the treatment group were lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, portal vein diameter, spleen thickness, and spleen vein diameter in the two groups were significantly reduced, and the difference was statistically significant in the same group (P<0.05). After treatment, portal vein diameter and spleen thickness in the treatment group were less than those in the control group, with significant difference between two groups (P<0.05). After treatment, liver fibrosis stage, HBV-DNA, and ALT in the two groups were significantly reduced, and the difference was statistically significant in the same group (P<0.05). After treatment, liver fibrosis stage, HBV-DNA, and ALT in the treatment group were lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the ALT normalization rates in the control and treatment groups were 93.88% and 100.00%, respectively, and there were differences between two groups (P<0.05). Conclusion Dangfei Liganning capsules combined with Fuzheng Huayu Capsules has synergistic effects in treatment of chronic hepatitis B with liver fibrosis, and can significantly improve liver function, and reduce the liver fibrosis indexes, which has a certain clinical application value.